Ipsen is a French pharmaceutical company headquartered in Paris, France. It primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders. It is publicly traded on the Euronext Paris as part of the SBF 120 index.
Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation.…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis…
France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left…
France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for…
Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses,…
See our Cookie Privacy Policy Here
